Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion type Assertion NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_head.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion description "[This review focuses on three key molecular mechanisms of glucocorticoid resistance in IBD: (i) decreased cytoplasmic glucocorticoid concentration secondary to increased P-glycoprotein-mediated efflux of glucocorticoid from target cells due to overexpression of the multidrug resistance gene (MDR1); (ii) impaired glucocorticoid signaling because of dysfunction at the level of the glucocorticoid receptor; and (iii) constitutive epithelial activation of proinflammatory mediators, including nuclear factor kappa B, resulting in inhibition of glucocorticoid receptor transcriptional activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_provenance.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion evidence source_evidence_literature NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_provenance.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion SIO_000772 12967327 NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_provenance.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion wasDerivedFrom befree-20150227 NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_provenance.
- NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_assertion wasGeneratedBy ECO_0000203 NP434922.RAmdzZ8PxbvhfPm4NiNwANqCMJkloA3IJs1_xL010F9mQ130_provenance.